Want to see AU:M7T full AI Analyst Report?
M7T Stock Chart & Stats
AU$0.56
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.56
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.25 - AU$0.69
Previous CloseN/A
Volume428.94K
Average Volume (3M)368.13K
Market Cap
AU$68.15M
Enterprise ValueAU$60.81M
Total Cash (Recent Filing)AU$18.49M
Total Debt (Recent Filing)AU$1.75M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Sep 01, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding235,009,720
10 Day Avg. Volume349,234
30 Day Avg. Volume368,134
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)1.74
Price to Sales (P/S)2.35
P/FCF Ratio701.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.36Price Target Upside-36.61% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.2
Revenue Forecast (FY)AU$30.45M
Bulls Say, Bears Say
Bulls Say
Focused Enterprise Medical Imaging BusinessMach7’s narrow focus on enterprise medical imaging and integration across hospital systems is a durable competitive position. It aligns with structural digitization of imaging workflows and long procurement cycles in healthcare, supporting recurring enterprise deals and stable demand.
Low Leverage And Healthy Equity BaseA low-debt balance sheet and strong equity base provide financial flexibility for product investment, R&D, or selective M&A without immediate refinancing pressure. This reduces solvency risk and supports multi-quarter execution against growth plans.
Material Recent Top-line AccelerationA pronounced revenue lift indicates improving market traction and product adoption among hospitals and imaging departments. If sustained, higher scale can enable operating leverage, improve margins over time, and validate the go-to-market model.
Bears Say
Persistent Unprofitability And Negative MarginsOngoing negative EBIT and net margins, plus a negative ROE, show the business is not yet self-sustaining operationally. Persistent losses constrain reinvestment capacity, increase reliance on external capital, and raise execution risk over multiple quarters.
Volatile Cash Flow And Weak Cash ConversionInconsistent free cash flow and weak conversion from income to cash reduce predictability of internal funding for growth and operations. This diminishes resilience to shocks and could necessitate dilutive or costly financing to sustain execution.
Inconsistent Revenue Trends And Earnings ErosionConflicting or uneven top-line metrics and a steep EPS decline highlight instability in demand or margin dynamics. Such variability complicates multi-quarter forecasting, undermines confidence in sustainable growth, and stresses operational planning.
Mach7 Technologies News
M7T FAQ
What was Mach7 Technologies Ltd.’s price range in the past 12 months?
Mach7 Technologies Ltd. lowest share price was AU$0.24 and its highest was AU$0.69 in the past 12 months.
What is Mach7 Technologies Ltd.’s market cap?
Mach7 Technologies Ltd.’s market cap is AU$68.15M.
When is Mach7 Technologies Ltd.’s upcoming earnings report date?
Mach7 Technologies Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 61 days.
How were Mach7 Technologies Ltd.’s earnings last quarter?
Mach7 Technologies Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.024 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.019.
Is Mach7 Technologies Ltd. overvalued?
According to Wall Street analysts Mach7 Technologies Ltd.’s price is currently Overvalued.
Does Mach7 Technologies Ltd. pay dividends?
Mach7 Technologies Ltd. does not currently pay dividends.
What is Mach7 Technologies Ltd.’s EPS estimate?
Mach7 Technologies Ltd.’s EPS estimate is -0.03.
How many shares outstanding does Mach7 Technologies Ltd. have?
Mach7 Technologies Ltd. has 235,009,720 shares outstanding.
What happened to Mach7 Technologies Ltd.’s price movement after its last earnings report?
Mach7 Technologies Ltd. reported an EPS of -AU$0.024 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Mach7 Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:M7T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mach7 Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.36 (-36.61% Downside)
AU$0.36 (-36.61% Downside)
Blogger Sentiment
Bullish
AU:M7T Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$249.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.50%
12-Months-Change
Fundamentals
Return on Equity
-23.86%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Mach7 Technologies Ltd.
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients’ medical images; vendor-neutral archive (VNA), a vendor-agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. The company also provides workflow applications, such as a universal worklist, quality control (QC) tools designed for technologists’ workflows; image sharing and exchange capabilities; teleradiology services; and additional specialized tools to serve departmental patient care needs. Mach7 Technologies Limited was founded in 2007 and is headquartered in South Burlington, Vermont.
M7T Company Deck
M7T Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a constructive operational pivot: management presented a clear strategic reset, measurable cost reductions (payments down 9% YoY, 6% QoQ), stronger cash flow (positive operating cash flow in Q2), a stable ARR run rate of $23M, and early commercial/product milestones (first Flamingo customer, CE certificate). These positives are tempered by a near-term reduction in CARR of $2.9M (removal of the NTP project), the strategic exit from the VHA program that reduced backlog but improves long-term margin prospects, lingering VNA/KLAS performance work that may take 12–24 months to fully resolve, and a CTO search following the CIO departure. Overall, the highlights (stabilized ARR, improved cash and cost discipline, new product momentum and regulatory/market expansion) outweigh the lowlights, although several improvements will take time to flow through revenue.View all AU:M7T earnings summariesM7T Stock 12 Month Forecast
Average Price Target
AU$0.36
▼(-36.61% Downside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Beamtree Holdings Ltd
―
Artrya Limited
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---